Influence of multiple courses of therapy on aminoglycoside clearance in adult patients with cystic fibrosis

Sarah S A A Sh Alghanem, Iona Paterson, Daan Touw, Alison Thomson

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

The objectives of this article are to investigate factors affecting aminoglycoside clearance in adult patients with cystic fibrosis who received multiple courses of antibiotic therapy over a period of up to 15 years. Aminoglycoside concentration–time data and relevant clinical characteristics were collated from clinical pharmacokinetic databases established in Glasgow, Scotland and The Hague, The Netherlands. Data from Glasgow (1993–2009) were used for population model development; data from The Hague (2002–11) were used for model validation. NONMEM was used to determine structural and covariate models, with a particular focus on between-occasion variability and changes in aminoglycoside handling over multiple courses of therapy. The Glasgow dataset comprised 1075 courses of aminoglycoside therapy (96% tobramycin and 4% gentamicin) in 166 patients and included 2238 concentration measurements. The data were best described by a two-compartment model with creatinine clearance and height influencing aminoglycoside clearance, and height influencing volume of distribution. Between-subject and between-occasion variabilities in clearance were low, at 18% and 11%, respectively; between-subject variability was 12% for volume of distribution. Internal and external model validations were satisfactory. Multiple courses of therapy (ranging from 2 to 28 courses per patient) were not associated with any systematic changes in aminoglycoside clearance. In conclusion, height was a better descriptor of aminoglycoside pharmacokinetics than weight in adult patients with cystic fibrosis. No changes in clearance were observed over time, even in patients who had received multiple courses of therapy over several years.
Original languageEnglish
Pages (from-to)1338-1347
Number of pages10
JournalJournal of Antimicrobial Chemotherapy
Volume68
Issue number6
Early online date23 Feb 2013
DOIs
Publication statusPublished - Jun 2013

Fingerprint

Aminoglycosides
Cystic Fibrosis
Therapeutics
Pharmacokinetics
Tobramycin
Structural Models
Scotland
Gentamicins
Netherlands
Creatinine
Databases
Anti-Bacterial Agents
Weights and Measures
Population

Keywords

  • lung infection
  • nephrotoxicity
  • model validation
  • interoccasion variability

Cite this

@article{b21a00030f6a40fd982ddd9d08ebd005,
title = "Influence of multiple courses of therapy on aminoglycoside clearance in adult patients with cystic fibrosis",
abstract = "The objectives of this article are to investigate factors affecting aminoglycoside clearance in adult patients with cystic fibrosis who received multiple courses of antibiotic therapy over a period of up to 15 years. Aminoglycoside concentration–time data and relevant clinical characteristics were collated from clinical pharmacokinetic databases established in Glasgow, Scotland and The Hague, The Netherlands. Data from Glasgow (1993–2009) were used for population model development; data from The Hague (2002–11) were used for model validation. NONMEM was used to determine structural and covariate models, with a particular focus on between-occasion variability and changes in aminoglycoside handling over multiple courses of therapy. The Glasgow dataset comprised 1075 courses of aminoglycoside therapy (96{\%} tobramycin and 4{\%} gentamicin) in 166 patients and included 2238 concentration measurements. The data were best described by a two-compartment model with creatinine clearance and height influencing aminoglycoside clearance, and height influencing volume of distribution. Between-subject and between-occasion variabilities in clearance were low, at 18{\%} and 11{\%}, respectively; between-subject variability was 12{\%} for volume of distribution. Internal and external model validations were satisfactory. Multiple courses of therapy (ranging from 2 to 28 courses per patient) were not associated with any systematic changes in aminoglycoside clearance. In conclusion, height was a better descriptor of aminoglycoside pharmacokinetics than weight in adult patients with cystic fibrosis. No changes in clearance were observed over time, even in patients who had received multiple courses of therapy over several years.",
keywords = "lung infection, nephrotoxicity, model validation, interoccasion variability",
author = "Alghanem, {Sarah S A A Sh} and Iona Paterson and Daan Touw and Alison Thomson",
year = "2013",
month = "6",
doi = "10.1093/jac/dkt035",
language = "English",
volume = "68",
pages = "1338--1347",
journal = "Journal of Antimicrobial Chemotherapy",
issn = "0305-7453",
number = "6",

}

Influence of multiple courses of therapy on aminoglycoside clearance in adult patients with cystic fibrosis. / Alghanem, Sarah S A A Sh; Paterson, Iona; Touw, Daan; Thomson, Alison.

In: Journal of Antimicrobial Chemotherapy, Vol. 68, No. 6, 06.2013, p. 1338-1347.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Influence of multiple courses of therapy on aminoglycoside clearance in adult patients with cystic fibrosis

AU - Alghanem, Sarah S A A Sh

AU - Paterson, Iona

AU - Touw, Daan

AU - Thomson, Alison

PY - 2013/6

Y1 - 2013/6

N2 - The objectives of this article are to investigate factors affecting aminoglycoside clearance in adult patients with cystic fibrosis who received multiple courses of antibiotic therapy over a period of up to 15 years. Aminoglycoside concentration–time data and relevant clinical characteristics were collated from clinical pharmacokinetic databases established in Glasgow, Scotland and The Hague, The Netherlands. Data from Glasgow (1993–2009) were used for population model development; data from The Hague (2002–11) were used for model validation. NONMEM was used to determine structural and covariate models, with a particular focus on between-occasion variability and changes in aminoglycoside handling over multiple courses of therapy. The Glasgow dataset comprised 1075 courses of aminoglycoside therapy (96% tobramycin and 4% gentamicin) in 166 patients and included 2238 concentration measurements. The data were best described by a two-compartment model with creatinine clearance and height influencing aminoglycoside clearance, and height influencing volume of distribution. Between-subject and between-occasion variabilities in clearance were low, at 18% and 11%, respectively; between-subject variability was 12% for volume of distribution. Internal and external model validations were satisfactory. Multiple courses of therapy (ranging from 2 to 28 courses per patient) were not associated with any systematic changes in aminoglycoside clearance. In conclusion, height was a better descriptor of aminoglycoside pharmacokinetics than weight in adult patients with cystic fibrosis. No changes in clearance were observed over time, even in patients who had received multiple courses of therapy over several years.

AB - The objectives of this article are to investigate factors affecting aminoglycoside clearance in adult patients with cystic fibrosis who received multiple courses of antibiotic therapy over a period of up to 15 years. Aminoglycoside concentration–time data and relevant clinical characteristics were collated from clinical pharmacokinetic databases established in Glasgow, Scotland and The Hague, The Netherlands. Data from Glasgow (1993–2009) were used for population model development; data from The Hague (2002–11) were used for model validation. NONMEM was used to determine structural and covariate models, with a particular focus on between-occasion variability and changes in aminoglycoside handling over multiple courses of therapy. The Glasgow dataset comprised 1075 courses of aminoglycoside therapy (96% tobramycin and 4% gentamicin) in 166 patients and included 2238 concentration measurements. The data were best described by a two-compartment model with creatinine clearance and height influencing aminoglycoside clearance, and height influencing volume of distribution. Between-subject and between-occasion variabilities in clearance were low, at 18% and 11%, respectively; between-subject variability was 12% for volume of distribution. Internal and external model validations were satisfactory. Multiple courses of therapy (ranging from 2 to 28 courses per patient) were not associated with any systematic changes in aminoglycoside clearance. In conclusion, height was a better descriptor of aminoglycoside pharmacokinetics than weight in adult patients with cystic fibrosis. No changes in clearance were observed over time, even in patients who had received multiple courses of therapy over several years.

KW - lung infection

KW - nephrotoxicity

KW - model validation

KW - interoccasion variability

UR - http://jac.oxfordjournals.org/content/by/year

U2 - 10.1093/jac/dkt035

DO - 10.1093/jac/dkt035

M3 - Article

VL - 68

SP - 1338

EP - 1347

JO - Journal of Antimicrobial Chemotherapy

JF - Journal of Antimicrobial Chemotherapy

SN - 0305-7453

IS - 6

ER -